Affiliation:
1. WHO HPV LabNet Global Reference Laboratory, Department of Clinical Microbiology
2. Department of Laboratory Medicine, Lund University, Malmö University Hospital, SE-20502 Malmö, Sweden
3. Department of Clinical Chemistry and Pharmacology, Lund University Hospital, SE-22185 Lund, Sweden
Abstract
Human papillomavirus (HPV) infection is a necessary cause of cervical cancer and cervical dysplasia. Accurate and sensitive genotyping of multiple oncogenic HPVs is essential for a multitude of both clinical and research uses. We developed a modified general primer (MGP) PCR system with five forward and five reverse consensus primers. The MGP system was compared to the classical HPV general primer system GP5+/6+ using a proficiency panel with HPV plasmid dilutions as well as cervical samples from 592 women with low-grade cytological abnormalities. The reference method (GP5+/6+) had the desirable high sensitivity (five copies/PCR) for five oncogenic HPV types (HPV type 16 [HPV-16], HPV-18, HPV-56, HPV-59, and HPV-66). The MGP system was able to detect all 14 oncogenic HPV types at five copies/PCR. In the clinical samples, the MGP system detected a significantly higher proportion of women with more than two concomitant HPV infections than did the GP5+/6+ system (102/592 women compared to 42/592 women). MGP detected a significantly greater number of infections with HPV-16, -18, -31, -33, -35, -39, -42, -43, -45, -51, -52, -56, -58, and -70 than did GP5+/6+. In summary, the MGP system primers allow a more sensitive amplification of most of the HPV types that are established as oncogenic and had an improved ability to detect multiple concomitant HPV infections.
Publisher
American Society for Microbiology
Reference22 articles.
1. Bae, J. H., C. J. Kim, T. C. Park, S. E. Namkoong, and J. S. Park. 2007. Persistence of human papillomavirus as a predictor for treatment failure after loop electrosurgical excision procedure. Int. J. Gynecol. Cancer 17:1271-1277.
2. Bosch, F. X., M. M. Manos, N. Munoz, M. Sherman, A. M. Jansen, J. Peto, M. H. Schiffman, V. Moreno, R. Kurman, K. V. Shah, et al. 1995. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. J. Natl. Cancer Inst. 87:796-802.
3. Brink, A. A., P. J. Snijders, C. J. Meijer, J. Berkhof, and R. H. Verheijen. 2006. HPV testing in cervical screening. Best Pract. Res. Clin. Obstet. Gynaecol. 20:253-266.
4. Castle, P. E. 2008. Invited commentary: is monitoring of human papillomavirus infection for viral persistence ready for use in cervical cancer screening? Am. J. Epidemiol. 168:138-144.
5. Clifford, G., S. Franceschi, M. Diaz, N. Munoz, and L. L. Villa. 2006. HPV type-distribution in women with and without cervical neoplastic diseases. Vaccine 24(Suppl. 3):S3/26-34.
Cited by
127 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献